Uslu, S. Et Al. 2018. THE EFFICACY AND DRUG SURVIVAL OF THE BIOSIMILAR INFLIXIMAB (CT-P13) COMPARED TO THE ORIGINAL REFERENCE INFLIXIMAB IN INFLAMMATORY RHEUMATIC DISEASES; RESULTS FROM THE TURKBIO REGISTRY. Congress of the European-League-Against-Rheumatism (EULAR) , (Amsterdam, Netherlands), 329.

Uslu, S., Can, G., Senel, S., DALKILIÇ, H. E., Inanc, N., Akar, S., ... Kocaer, S. B.(2018). THE EFFICACY AND DRUG SURVIVAL OF THE BIOSIMILAR INFLIXIMAB (CT-P13) COMPARED TO THE ORIGINAL REFERENCE INFLIXIMAB IN INFLAMMATORY RHEUMATIC DISEASES; RESULTS FROM THE TURKBIO REGISTRY . Congress of the European-League-Against-Rheumatism (EULAR) (pp.329). Amsterdam, Netherlands

Uslu, S. Et Al. "THE EFFICACY AND DRUG SURVIVAL OF THE BIOSIMILAR INFLIXIMAB (CT-P13) COMPARED TO THE ORIGINAL REFERENCE INFLIXIMAB IN INFLAMMATORY RHEUMATIC DISEASES; RESULTS FROM THE TURKBIO REGISTRY," Congress of the European-League-Against-Rheumatism (EULAR), Amsterdam, Netherlands, 2018

Uslu, S. Et Al. "THE EFFICACY AND DRUG SURVIVAL OF THE BIOSIMILAR INFLIXIMAB (CT-P13) COMPARED TO THE ORIGINAL REFERENCE INFLIXIMAB IN INFLAMMATORY RHEUMATIC DISEASES; RESULTS FROM THE TURKBIO REGISTRY." Congress of the European-League-Against-Rheumatism (EULAR) , Amsterdam, Netherlands, pp.329, 2018

Uslu, S. Et Al. (2018) . "THE EFFICACY AND DRUG SURVIVAL OF THE BIOSIMILAR INFLIXIMAB (CT-P13) COMPARED TO THE ORIGINAL REFERENCE INFLIXIMAB IN INFLAMMATORY RHEUMATIC DISEASES; RESULTS FROM THE TURKBIO REGISTRY." Congress of the European-League-Against-Rheumatism (EULAR) , Amsterdam, Netherlands, p.329.

@conferencepaper{conferencepaper, author={S. Uslu Et Al. }, title={THE EFFICACY AND DRUG SURVIVAL OF THE BIOSIMILAR INFLIXIMAB (CT-P13) COMPARED TO THE ORIGINAL REFERENCE INFLIXIMAB IN INFLAMMATORY RHEUMATIC DISEASES; RESULTS FROM THE TURKBIO REGISTRY}, congress name={Congress of the European-League-Against-Rheumatism (EULAR)}, city={Amsterdam}, country={Netherlands}, year={2018}, pages={329} }